The stock of IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) is a huge mover today! The stock increased 7.14% or $0.15 on October 3, hitting $2.25. About 587,808 shares traded hands or 148.52% up from the average. IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) has declined 13.93% since February 29, 2016 and is downtrending. It has underperformed by 26.15% the S&P500.
The move comes after 7 months positive chart setup for the $59.06M company. It was reported on Oct, 3 by Barchart.com. We have $3.20 PT which if reached, will make NASDAQ:IPCI worth $24.81 million more.
Analysts await IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) to report earnings on October, 14. They expect $-0.07 earnings per share, up 12.50% or $0.01 from last year’s $-0.08 per share. After $-0.08 actual earnings per share reported by IntelliPharmaCeutics Intl Inc (USA) for the previous quarter, Wall Street now forecasts -12.50% EPS growth.
According to Zacks Investment Research, “Intellipharmaceutics International Inc. is engaged in the research, development, and commercialization of controlled-release and targeted pharmaceutical products. Its products include Effexor XR and Protonix. The Company offers products in different stages of development in therapeutic areas, including neurology, cardiovascular, and GIT. Intellipharmaceutics International Inc. was formerly known as IntelliPharmaCeutics Ltd. and is based in Toronto, Canada.”
Another recent and important IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) news was published by Benzinga.com which published an article titled: “15 Stocks Moving In Friday’s Pre-Market Session” on September 23, 2016.
IPCI Company Profile
Intellipharmaceutics International Inc., incorporated on October 22, 2009, is a pharmaceutical firm specializing in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. The Company’s Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, the Company has developed several drug delivery systems and a pipeline of products and product candidates at various stages of development in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract (GIT), diabetes and pain. The Hypermatrix family of technologies includes IntelliFoam, IntelliGITransporter, IntelliMatrix, IntelliOsmotics, IntelliPaste, IntelliPellets, IntelliShuttle, Point of Divergence Drug Delivery System (nPODDDS) and Paradoxical OverDose Resistance Activating System (PODRAS).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.